BICALOX

This brand name is authorized in Australia, Hong Kong SAR China, New Zealand, Singapore, South Africa, Tunisia.

Active ingredients

The drug BICALOX contains one active pharmaceutical ingredient (API):

1	Bicalutamide UNII A0Z3NAU9DP - BICALUTAMIDE
	Bicalutamide is a non-steroidal antiandrogen, devoid of other endocrine activity. It binds to androgen receptors without activating gene expression, and thus inhibits the androgen stimulus. Regression of prostatic tumours results from this inhibition.
	Read more about Bicalutamide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BICALOX Film-coated tablet	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BB03	Bicalutamide	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BB Anti-androgens
Discover more medicines within L02BB03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8094B
HK	Department of Health Drug Office	59232
NZ	Medicines and Medical Devices Safety Authority	12570
SG	Health Sciences Authority	14145P
TN	Direction de la Pharmacie et du Médicament	17083021
ZA	Health Products Regulatory Authority	41/21.12/0818